John Walter Erickson V, | |
865 Central Ave, Dover, NH 03820-2506 | |
(603) 749-6112 | |
Not Available |
Full Name | John Walter Erickson V |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 865 Central Ave, Dover, New Hampshire |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1265094049 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 4290 (New Hampshire) | Primary |
Mailing Address | Practice Location Address |
---|---|
John Walter Erickson V, 20 Timber Ln, Methuen, MA 01844-4659 Ph: (928) 863-4356 | John Walter Erickson V, 865 Central Ave, Dover, NH 03820-2506 Ph: (603) 749-6112 |
News Archive
GE Capital, Healthcare Financial Services has provided $31.5 million as part of a $145 million senior secured credit facility for Harden Healthcare, LLC. Harden will use the proceeds of the financing to provide additional growth capital and to refinance its existing debt facilities. GE Capital is the administrative agent for the credit facility. GE Capital Markets served as co-lead arranger and joint bookrunner.
Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.
New research suggests that there could be health hazards associated with consuming excessive amounts of beta-carotene.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration
Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that can cause vision loss.
› Verified 6 days ago
Katherine Anne Lombard, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 30 Grapevine Dr, Dover, NH 03820 Phone: 603-749-2374 Fax: 603-749-2051 | |
Mollie Pettigrew, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 679 Central Ave, Dover, NH 03820 Phone: 603-742-5313 | |
John Zinka, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 30 Grapevine Dr, Dover, NH 03820 Phone: 603-749-2374 | |
Cheryl Fratamico, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 833 Central Ave, Dover, NH 03820 Phone: 603-749-9363 | |
Dr. Sonya Anne Kara, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-740-2512 | |
Christine Ouellette Morrison, R.PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 118 Central Ave, Dover, NH 03820 Phone: 603-742-3995 Fax: 603-742-8180 | |
Amanda Houle, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 833 Central Ave, Dover, NH 03820 Phone: 603-749-9361 |